Phase 1b/2a, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination With Durvalumab in Patients With Advanced Non Small Cell Lung Cancer Who Progressed Following Platinum-based Chemotherapy
Latest Information Update: 16 Apr 2025
At a glance
- Drugs Durvalumab (Primary) ; Vactosertib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors MedPacto
Most Recent Events
- 25 Mar 2025 Status changed from active, no longer recruiting to completed.
- 09 Dec 2024 Planned End Date changed from 30 Dec 2022 to 23 Dec 2024.
- 18 Jun 2024 Results published in the MedPacto Media Release.